[December 16, 2014]

ZS Genetics, Inc., Developer of a Unique and Potentially Disruptive "Third-Generation" DNA Sequencing Technology Platform, Announces Organization Change to Accelerate Strategic Plans

ZS Genetics, Inc., developer of a unique and potentially disruptive "Third-Generation" DNA sequencing technology platform, announced today that current board member and life sciences industry veteran, John A. McCarthy, Jr., has joined the company as Chief Executive Officer. Mr. McCarthy's CEO appointment signifies an important and accelerated focus on near-term prototype completion and product development, commercial planning, and strategic financing and corporate partnership execution. Bill Ward, ion microscopy entrepreneur, is retiring as company President, but will be playing an important and complementary role as a key member of the company's world-class Scientific Advisory Board.

ZS Genetics' technology platform utilizes state-of-the-art electron microscopy, as well as proprietary intellectual property developed by the company, to introduce the world's first high-accuracy, long-read, single-molecule DNA sequencing platform at operating metrics never before seen by the industry. The company expects to achieve major technical milestones and prototype development shortly. Successful development and integration of ZS Genetics' third-generation DNA sequencing technology into industry is expected to have a major impact on critical research initiatives underway in oncology, infectious disease and the microbiome, and eventually numerous important clinical applications.

"As Founder and Chief Technology Officer of ZS Genetics, I'm thrilled that John has agreed to join the company as CEO at this critical inflection point of our product and strategic development, and I look forward to ur close working partnership as we scale our business," stated William R. Glover III. "John's track record of success in navigating and driving the development of pioneering science-based technologies, while forging critically important strategic corporate partnerships with industry-leading global organizations, represents the ideal skill set to ensure our near- and long-term success," commented Lead Independent Director, Thomas A. Shields, a major investor, together with Peter F. Shields.

Prior to joining ZS Genetics as CEO, Mr. McCarthy served as CEO and Director of CryoXtract Instruments, a private-equity funded developer of unique automation products and solutions for the worldwide life sciences industry. Over the past 25 years, Mr. McCarthy has led the transformational growth of numerous science- and technology-based companies from early-stage organizations into successful commercial entities, both in the private and public markets (including three IPOs). Mr. McCarthy's track record includes successfully raising more than $1 billion across the broad capital markets, as well as developing, executing and managing numerous precedent-setting strategic corporate partnerships.

Prior to CryoXtract Instruments, Mr. McCarthy was President and CEO of Qteros, Inc., a leading technology company in the alternative energy industry that partnered with some of the industry's top global organizations. Before Qteros, Mr. McCarthy served in various executive positions at leading technology companies, including Microbia Inc., Verenium Corporation, Synta Pharmaceuticals, Inc. and Exact Sciences Corporation, as well as in the Investment Banking Group of Morgan Stanley. Mr. McCarthy currently serves as Chairman of the Board of publicly traded InVivo Therapeutics, a leading biomaterials company focused on traumatic spinal cord injuries. He graduated with high honors from Lehigh University and received an MBA degree from the Harvard Business School.

"I'm excited about expanding my board role to join as CEO given the scientific and commercial imperative we all feel to rapidly introduce this vitally important technology platform into the scientific community," stated John McCarthy. "The full ZS Genetics team looks forward to numerous exciting developments and announcements over the very near future."

About ZS Genetics, Inc.

ZS Genetics, Inc. is a privately held Massachusetts company focused on developing a unique and potentially disruptive "Third-Generation" DNA sequencing technology platform for the global research and clinical marketplace. ZS Genetics' technology platform utilizes state-of-the-art election microscopy and proprietary intellectual property developed by the company to introduce the world's first high-accuracy, long-read, single-molecule DNA sequencing platform at operating metrics never before seen by the industry. ZS Genetics' technology platform offers the prospect of meaningful accelerated success across major oncology, infectious disease and microbiome research initiatives.

[ Back To TMCnet.com's Homepage ]